双模态磁共振成像与生物发光成像定量评估间充质干细胞在胶质瘤中的植入状态
本研究将过表达铁蛋白重链(FTH)和萤火虫荧光素酶(FLUC)报告基因的间充质干细胞(MSCs)经瘤周、瘤内、动脉内和静脉内四种途径移植入颅内C6胶质瘤Wistar大鼠,用MRI和生物发光成像(BLI)监测。BLI定量显示瘤周注射(61%)和瘤内注射(71%)的MSCs在胶质瘤中的百分比显著高于动脉内注射(30%)和静脉内注射(0%)。结论认为瘤周递送FTH-FLUC-MSCs可实现稳健植入,可能作为治疗恶性胶质瘤的最佳递送途径。
要点
- BLI定量显示瘤内注射71%、瘤周注射61%的MSCs位于胶质瘤内,显著高于动脉内注射30%和静脉内注射0%。
- 瘤周注射的MSCs在注射后11天仍有约6%保留在肿瘤内,而其他途径注射的细胞至第11天均不可检测。
- 瘤周、瘤内和动脉内注射的FTH-FLUC-MSCs在体内经MRI和BLI检测均向颅内胶质瘤特异性迁移。
核心结论
- 瘤周递送FTH-FLUC-MSCs可实现稳健植入,可能作为治疗恶性胶质瘤的最佳递送途径。
研究设计与样本
- 动物实验:将过表达FTH和FLUC报告基因的MSCs经瘤周、瘤内、动脉内和静脉内四种途径注射入颅内C6胶质瘤Wistar大鼠,用MRI和BLI在体内监测。
关键影像表现/征象
- 经瘤周、瘤内和动脉内途径注射的FTH-FLUC-MSCs在体内经MRI和BLI检测均向颅内胶质瘤特异性迁移。
- BLI信号强度定量显示,瘤周注射组MSCs在胶质瘤中的百分比为61%,瘤内注射组为71%,动脉内注射组为30%,静脉内注射组为0%。
- 瘤周注射的FTH-FLUC-MSCs逐渐减少,注射后11天仍有约6%保留在肿瘤内;其他途径注射的MSCs数量迅速下降,注射后第11天均不可检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The tumor-tropic properties of mesenchymal stem cells (MSCs) enable them to serve as appealing cellular vehicles for delivering therapeutic agents to treat malignant glioma. However, the exact engraftment status of MSCs in glioma via different administration routes remains unclear due to the lack of quantitative analysis. This study aimed to quantify the engraftment of MSCs in glioma after administration via different routes using non-invasive dual-modality magnetic resonance imaging (MRI) and bioluminescence imaging (BLI).
MATERIALS AND METHODS: MSCs were transduced with a lentivirus overexpressing ferritin heavy chain (FTH) and firefly luciferase (FLUC) reporter genes to yield FTH- and FLUC-overexpressed MSCs (FTH-FLUC-MSCs). Wistar rats bearing intracranial C6 glioma received peritumoral, intratumoral, intra-arterial, and intravenous injection of FTH-FLUC-MSCs, respectively. MRI and BLI were performed to monitor FTH-FLUC-MSCs in vivo.
RESULTS: FTH-FLUC-MSCs administered via peritumoral, intratumoral and intra-arterial routes migrated specially toward the intracranial glioma in vivo, as detected by MRI and BLI. As quantified by the BLI signal intensity, the percentages of FTH-FLUC-MSCs in the glioma were significantly higher with peritumoral injection (61%) and intratumoral injection (71%) compared to intra-arterial injection (30%) and intravenous injection (0%). Peritumorally injected FTH-FLUC-MSCs showed a gradual decline, with approximately 6% of FTH-FLUC-MSCs still retained within the tumor up to 11 days after injection. Meanwhile, the number of FTH-FLUC-MSCs injected via other routes dropped quickly, and none were detectable by day 11 post-injection.
CONCLUSION: Peritumoral delivery of FTH-FLUC-MSCs offers robust engraftment and could be used as the optimal delivery route for treating malignant glioma.
引用
- Cao M, Li Y, Tang Y, et al. Quantification of the Engraftment Status of Mesenchymal Stem Cells in Glioma Using Dual-Modality Magnetic Resonance Imaging and Bioluminescence Imaging. Acad Radiol. 2024. PMID: 39054246. doi:10.1016/j.acra.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。